



MEDIA CONTACT:  
Myren Bobryk-Ozaki  
(619)-555-7986  
Myren.Bobryk-Ozaki@resmed.com

*FOR IMMEDIATE RELEASE*  
**News Backgrounder**

### **Backgrounder – ResMed Unveils Brand New AI-Powered CPAP Machine**

**SAN DIEGO, December 8, 2023** – ResMed (NYSE: RMD, ASX: RMD) is expanding its Continuous Positive Airway Pressure (CPAP) machine product portfolio to include an artificial intelligence-powered machine in the AirSense™ 12 series, the AirIntell™ Adapt. The innovative product will be available for purchase on December 11th.

Millions of people have forms of sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases that affect their quality of life. The AirIntell™ Adapt addresses the needs of these people by taking the guesswork out of the picture using innovative artificial intelligence. It includes all the advantages and advancements of artificial intelligence technology including high-level adaptation, fast and accurate decision-making, frequent and comprehensive reporting and ease of use and accessibility. The AirIntell™ Adapt is available for purchase worldwide, in all 140+ countries ResMed services.

When the new machine went into clinical trials, CPAP users preferred the capabilities of the AirIntell™ Adapt to previous AutoSense and VPAP models. Approximately 41.3% of users preferred it on day one, doubling its preference rating by the end of week two with an increase to nearly 85.9%. Users reported the AirIntell™ Adapt to be quick in its adjustments to their sleeping patterns, easy compatibility to their existing tubes and masks as well as simple and convenient reports on their sleep through the myAir app.

ResMed's driving purpose is to make a positive impact on the lives of everyday people with a 2025 goal to change the lives of 250 million people. In the last 12 months, ResMed has changed 156 million lives and the AirIntell™ Adapt will only continue to drive that impact further.

The evolution and ongoing development of artificial intelligence-focused technologies invigorated ResMed to start work on the AirIntell™ Adapt in 2021. Previous Variable Continuous Positive Airway Pressure (VPAP) and AutoSense models have paved the path for this development. VPAP models use two levels, often referred to as bi-level, that switch for each inhale and exhale respectively. AutoSense, also known as Automatic Continuous Positive Airway Pressure (APAP), models make automatic adjustments based on breathing pressure. The AirIntell™ Adapt builds on both of these existing designs and functions while implementing the continuous learning of artificial intelligence.

ResMed (NYSE: RMD, ASX: RMD) was founded in 1989 with the goal of pioneering innovative solutions to enable better care and improve quality of life while lowering overall costs of healthcare systems that keep people healthy. Operating in over 140 countries, ResMed provides transformational care with cloud-connected medical devices and software platforms for professionals, caregivers and people with chronic conditions that impact their sleeping patterns.

# # #